BofA analyst Jason Gerberry downgraded ProKidney to Neutral from Buy with a price target of $2, down from $8. The analyst views 2024 as a “catalyst-light year” for the company given the uncertainty of the Phase 3 interim Proact-1 data. The firm cites a more conservative nominal peak sales outlook for the downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PROK:
- ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
- ProKidney appoints Nikhil Pereira-Kamath as Chief Business Officer
- ProKidney files $500M mixed securities shelf
- ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
- ProKidney price target lowered to $6 from $15 at Citi
